Article Link: www.tandfonline.com/doi/full/10.... (reach out if you want a copy)
tandfonline.com
Pathological and anatomical repository training networks (PART Net): A database and influence analysis
The primary purpose of this article is to introduce the Pathological and Anatomical Repository Training Networks (PART Net) database. The database is a collection of information on historic anatomi...
![Title page on chapter "Failures to Communicate: Rhetorical Problems in COI" Intro starts: Conflicting or competing interests, sometimes rendered as COI, are generally understood in terms of incompatibilities between ethical and fiduciary responsibilities or some other obligation, relationship, or motivation [1]. Columbia University’s Department of Medical Humanities and Ethics notes an “inherent” “potential for conflict of interest…in industry-medicine relationships” because the ethical motives of profit-driven enterprises focus on shareholder interests, while healthcare providers must protect patient welfare [2]. Bernard Lo and Marilyn Fields [3] observe that industry-medicine partnerships provide vital social benefits, especially for healthcare, suggesting that striking a balance between competing interests is worthwhile. Although conflict of interest statements are commonly made, and more commonly required, problems seemingly remain as inevitable as they were in 1998 when editor Richard Smith called for general transparency in financial relationships [4]. Despite many tools and guidelines intended to meet this aim [1, 5–10], researchers continue to comment on problems with disclosures [11–13].](https://cdn.bsky.app/img/feed_thumbnail/plain/did:plc:em4abyeua3qk4ca6fy7vgoft/bafkreibw6clbydyzfgrb7mbsuyug6pgtpatg7lkga67jqo7jmy2oehqwwq)
![image of title page with intro starting "In the PARADIGM-HF trial, 8442 patients with heart failure were randomised to either the new drug Entresto (a combination of valsartan and sacubitril) or standard treatment with enalapril [1]. The trial was published in the prestigious New England Journal of Medicine, and the results showed that Entresto reduced death from cardiovascular causes or hospitalisation for heart failure by 4.7%. The trial was sponsored by Novartis, the manufacturer of Entresto, and the company participated in trial design and collected, managed, and analysed the data. Four of the eleven trial
authors were Novartis employees, and the seven academic authors had financial relationships with Novartis.](https://cdn.bsky.app/img/feed_thumbnail/plain/did:plc:em4abyeua3qk4ca6fy7vgoft/bafkreiaq7pzl4pv7trybshw54d5hr53efk2ji4e6k6pkmsvz3mxnhznryy)
![title page for Lexchin's article. Intro starts as follows: "Clinical trials form the basis for market approval, reimbursement, and the evidence
used in the practice of medicine [1], and trials that fail to demonstrate efficacy or
that raise important safety concerns can dramatically affect regulatory approval decisions, the sale of products after approval, or even the market value of the company [2]. Witness what happened following the July 2002 publication of the results of the Women’s Health Initiative (WHI) trial, which found that the estrogen/progestin combination caused an increased risk of cardiovascular disease and breast cancer
in postmenopausal women [3]. By June 2003, prescriptions for Prempro, the most widely sold estrogen/progestin combination, had declined by 66% in the United States (US) [4]."](https://cdn.bsky.app/img/feed_thumbnail/plain/did:plc:em4abyeua3qk4ca6fy7vgoft/bafkreibmns4byldyz2uub3xkf4bmjfusfsnqhanpzyylo3m2urppcgfple)
